NVOS has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NVOS has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Novo Integrated Sciences's gross profit for the three months ended in May. 2024 was $0.90 Mil. Novo Integrated Sciences's gross profit for the trailing twelve months (TTM) ended in May. 2024 was $5.09 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Novo Integrated Sciences's gross profit for the three months ended in May. 2024 was $0.90 Mil. Novo Integrated Sciences's Revenue for the three months ended in May. 2024 was $3.15 Mil. Therefore, Novo Integrated Sciences's Gross Margin % for the quarter that ended in May. 2024 was 28.46%.
Novo Integrated Sciences had a gross margin of 28.46% for the quarter that ended in May. 2024 => Competition eroding margins
During the past 13 years, the highest Gross Margin % of Novo Integrated Sciences was 41.09%. The lowest was 37.35%. And the median was 38.90%.
The historical data trend for Novo Integrated Sciences's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novo Integrated Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Aug17 | Aug18 | Aug19 | Aug20 | Aug21 | Aug22 | Aug23 | |||||||||||
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
3.52 | 3.06 | 3.82 | 4.80 | 4.95 |
Novo Integrated Sciences Quarterly Data | ||||||||||||||||||||
Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | May24 | |
Gross Profit | Get a 7-Day Free Trial |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
1.31 | 0.93 | 1.94 | 1.32 | 0.90 |
For the Medical Care Facilities subindustry, Novo Integrated Sciences's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Healthcare Providers & Services industry and Healthcare sector, Novo Integrated Sciences's Gross Profit distribution charts can be found below:
* The bar in red indicates where Novo Integrated Sciences's Gross Profit falls into.
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Novo Integrated Sciences's Gross Profit for the fiscal year that ended in Aug. 2023 is calculated as
Gross Profit (A: Aug. 2023 ) | = | Revenue | - | Cost of Goods Sold |
= | 12.572 | - | 7.619 | |
= | 4.95 |
Novo Integrated Sciences's Gross Profit for the quarter that ended in May. 2024 is calculated as
Gross Profit (Q: May. 2024 ) | = | Revenue | - | Cost of Goods Sold |
= | 3.152 | - | 2.255 | |
= | 0.90 |
Gross Profit for the trailing twelve months (TTM) ended in May. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $5.09 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
Novo Integrated Sciences's Gross Margin % for the quarter that ended in May. 2024 is calculated as
Gross Margin % (Q: May. 2024 ) | = | Gross Profit (Q: May. 2024 ) | / | Revenue (Q: May. 2024 ) |
= | (Revenue - Cost of Goods Sold) | / | Revenue | |
= | 0.90 | / | 3.152 | |
= | 28.46 % |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Novo Integrated Sciences (OTCPK:NVOS) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Novo Integrated Sciences had a gross margin of 28.46% for the quarter that ended in May. 2024 => Competition eroding margins
Thank you for viewing the detailed overview of Novo Integrated Sciences's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Sarfaraz Ali | director | C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Robert Letterio Oliva | director | 115 BELFIELD RD, TORONTO A6 L0J 1C0 |
Sterling M. Jimenez | officer: Principal Financial Officer | C/O NOVO INTEGRATED SCIENCES, INC.,, 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Michael Ross Pope | director | 1045 PROGRESS CIRCLE, LAWRENCEVILLE, GEORGIA GA 30043 |
Alex Flesias | director | 41 LANDMARK COURT, UNIONVILLE A6 L3R 9N7 |
Michael Joseph Gaynor | director | 49 BALMORAL ST, KEMPTVILLE A6 K0G 1J0 |
Robert Mattacchione | director, 10 percent owner, officer: Chief Executive Officer | 79 SELVAPIANO CRES, WOODBRIDGE A6 L4H 0X1 |
Pierre Joseph Dalcourt | director, 10 percent owner | 35 BRYANT ST , BOX 2230, HEARST A6 P0L 1N0 |
Christopher Mehlin David | director, officer: President | 10425 SE 22ND ST., BELLEVUE WA 98004 |
Thomas Edward Bray | officer: Principal Financial Officer | C/O NOVO INTEGRATED SCIENCES, INC., 11120 NE 2ND STREET, SUITE 100, BELLEVUE WA 98004 |
Rebecca Aw Mcdonald | officer: Chief Accounting Officer | 1301 INTERNATIONAL SPEEDWAY BLVD., DELAND FL 32724 |
James Jr Teters | director | 1200 FLIGHTLINE BLVD, STE 5, DELAN FL 32724 |
Phyllis Rouse | officer: secretary | 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724 |
Jay Hilden | officer: President & CEO | 1200 FLIGHLINE BLVD,, SUITE 5, DELAND FL 32724 |
Robert Adamo | director | 1200 FLIGHTLINE BOULEVARD, SUITE 5, DELAND FL 32724 |
From GuruFocus
By Business Wire • 11-06-2023
By Business Wire • 07-18-2024
By Business Wire • 08-24-2023
By Business Wire • 05-30-2024
By Business Wire • 08-15-2023
By Business Wire • 06-13-2024
By Business Wire • 07-19-2024
By Business Wire • 05-31-2024
By Business Wire • 10-06-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.